Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases

References

• Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):1–20. doi:https://doi.org/10.1093/occmed/kqm110.
   Google Scholar
• Pauna AM, Luca AC, Azoicăi D. Influenza vaccination. Advantages and disadvantages. SEA-Pract Appl Sci. 2019;7(20).131–6.
   Google Scholar
• Verma P, Thakur A, Deshmukh K, Jha A, Verma S. Routes of drug administration. Int J Pharm Stud Res. 2010;1:54–59.
   Google Scholar
• Shibata Y, Baba M, Kuniyuki M. Studies on the retention of passively transferred antibodies in man. II. Antibody activity in the blood after intravenous or intramuscular administration of anti-HBs human immunoglobulin. Vox Sang. 1983;45(1):77–82. doi:https://doi.org/10.1111/j.1423-0410.1983.tb04126.x.
   PubMedGoogle Scholar
• Reyneveld GI, Savelkoul HFJ, Parmentier HK. Current understanding of natural antibodies and exploring the possibilities of modulation using veterinary models. A review. Front Immunol. 2020;11(2139):2139. doi:https://doi.org/10.3389/fimmu.2020.02139.
   PubMedGoogle Scholar
• Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! Clin Immunol. 2020;216:108459. doi:https://doi.org/10.1016/j.clim.2020.108459.
   PubMed Web of Science ®Google Scholar
• Logue J, Crozier I, Jahrling PB, Kuhn JH. Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections. Expert Rev Vaccines. 2020;19(1):85–103. doi:https://doi.org/10.1080/14760584.2020.1713756.
   PubMedGoogle Scholar
• Gronski P, Seiler FR, Schwick HG. Discovery of antitoxins and development of antibody preparations for clinical uses from 1890 to 1990. Mol Immunol. 1991;28(12):1321–32. doi:https://doi.org/10.1016/0161-5890(91)90034-h.
   PubMedGoogle Scholar
• US Department of Health and Human Services. Guidance for industry - safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Rockville (MD): US Food and Drug Administration; 2008.
   Google Scholar
• Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma–aspects of yield and virus safety. Biotechnol J: Healthcare Nutr Technol. 2006;1(2):148–63. doi:https://doi.org/10.1002/biot.200500037.
   Google Scholar
• Buchacher A, Curling JM. Chapter 42 - Current manufacturing of human plasma immunoglobulin G. In: Jagschies G, Lindskog E, Łącki K, Galliher P, editors. Biopharmaceutical processing. Cambridge, MA: Elsevier; 2018. p. 857–76.
   Google Scholar
• Vandeberg P, Cruz M, Diez JM, Merritt WK, Santos B, Trukawinski S, Wellhouse A, José M, Willis T. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.11.18.388991.
   Google Scholar
• Kamada Ltd. KEDRAB (rabies immune globulin [human]). Full prescribing information. Negev (Israel): Kamada Ltd.; 2017.
   Google Scholar
• Emergent BioSolutions Canada Inc. CNJ-016 (Vaccinia immune globulin intravenous (Human) [VIGIV]). Full prescribing information. Winnipeg (Canada): Emergent BioSolutions Canada Inc.; 2017.
   Google Scholar
• CSL Behring. CytoGam® (Cytomegalovirus immune globulin intravenous (Human)). Full prescribing information. Kankakee (IL): CSL Behring; 2018.
   Google Scholar
• Saol Therapeutics Inc. HepaGam B® (hepatitis B immune globulin intravenous [human]). Full prescribing information. Roswell (GA, USA): Saol Therapeutics Inc.; 2018.
   Google Scholar
• Saol Therapeutics Inc. VARIZIG® ([Varicella zoster immune globulin (Human)]). Full prescribing information. Roswell (GA, USA): Saol Therapeutics Inc.; 2018.
   Google Scholar
• ADMA Biologics. Nabi-HB® (hepatitis B immune globulin [human]). Full prescribing information. Boca Raton (FL): ADMA Biologics; 2019.
   Google Scholar
• Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–18. doi:https://doi.org/10.1126/science.abd0831.
   PubMed Web of Science ®Google Scholar
• Lambkin R, McLain L, Jones SE, Aldridge SL, Dimmock NJ. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol. 1994;75(Pt 12):3493–502. doi:https://doi.org/10.1099/0022-1317-75-12-3493.
   PubMedGoogle Scholar
• Cao H, Shi Y. Convalescent plasma: possible therapy for novel coronavirus disease 2019. Transfusion. 2020;60(5):1078–83. doi:https://doi.org/10.1111/trf.15797.
   PubMedGoogle Scholar
• Schier JG, Wiener SW, Touger M, Nelson LS, Hoffman RS. Efficacy of Crotalidae polyvalent antivenin for the treatment of hognosed viper (Porthidium nasutum) envenomation. Ann Emerg Med. 2003;41(3):391–95. doi:https://doi.org/10.1067/mem.2003.81.
   PubMedGoogle Scholar
• Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, Chen Z, Slifka MK. Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis. Clin Infect Dis. 2016;62(9):1111–18. doi:https://doi.org/10.1093/cid/ciw066.
   PubMed Web of Science ®Google Scholar
• Joao C, Negi VS, Kazatchkine MD, Bayry J, Kaveri SV. Passive serum therapy to immunomodulation by IVIG: a fascinating journey of antibodies. J Immunol. 2018;200(6):1957–63. doi:https://doi.org/10.4049/jimmunol.1701271.
   PubMedGoogle Scholar
• Dunman PM, Nesin M. Passive immunization as prophylaxis: when and where will this work? Curr Opin Pharmacol. 2003;3(5):486–96. doi:https://doi.org/10.1016/j.coph.2003.05.005.
   PubMedGoogle Scholar
• Dixit R, Herz J, Dalton R, Booy R. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens. Vaccine. 2016;34(9):1152–61. doi:https://doi.org/10.1016/j.vaccine.2016.01.016.
   PubMedGoogle Scholar
• Gust AI. Role of passive immunotherapies in managing infectious outbreaks. Biologicals. 2012;40(3):196–99. doi:https://doi.org/10.1016/j.biologicals.2012.01.001.
   PubMedGoogle Scholar
• Bozzo J, Jorquera JI. Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. Expert Rev Anti Infect Ther. 2017;15(6):585–604. doi:https://doi.org/10.1080/14787210.2017.1328278.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Immune globulins. [accessed 2020 December 9]. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulins.
   Google Scholar
• Center for Biologic Evaluation and Research. List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. [accessed 2020 December 9]. https://www.fda.gov/media/89426/download.
   Google Scholar
• Grifols Therapeutics Inc. HyperRAB (Rabies immuno globulin (human). full prescribing information.). Full prescribing information. Research Triangle Park (NC, USA): Grifols: Grifols Therapeutics Inc.; 2019.
   Google Scholar
• Grifols Therapeutics Inc. GamaSTAN® S/D (immune globulin [human]). Full prescribing information. Research Triangle Park: Grifols Therapeutics Inc.; 2013.
   Google Scholar
• Centers for Disease Control and Prevention. FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep. 2012;61(12):212.
   PubMedGoogle Scholar
• Duchon JM, Levin MJ, Gershon AA. Safety and varicella outcomes in in utero-exposed newborns and preterm infants treated with varicella zoster immune globulin (VARIZIG): a subgroup analysis of an expanded-access program. J Pediatric Infect Dis Soc. 2020;9(4):449–53. doi:https://doi.org/10.1093/jpids/piz070.
   PubMedGoogle Scholar
• Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One. 2019;14(7):e0217749. doi:https://doi.org/10.1371/journal.pone.0217749.
   PubMedGoogle Scholar
• Mehrabi A, Esmaeilzadeh M, Fonouni H, Hafezi M, Rahbari NN, Golriz M, Majlesara A, Rad MT, Sadeghi M, Schmidt J. The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbeck’s Arch Surg. 2012;397(5):697–710. doi:https://doi.org/10.1007/s00423-011-0795-6.
   PubMedGoogle Scholar
• Emergent BioSolutions. ANTHRASIL (anthrax immune globulin intravenous [human]). Full prescribing information. Winnipeg (Canada): Emergent BioSolutions; 2015.
   Google Scholar
• Grifols Therapeutics Inc. HyperTET (Tetanus immune globulin (human). Full prescribing information.). Full Prescribing Information. Research Triangle Park (NC, USA): Grifols: Grifols Therapeutics Inc.; 2018.
   Google Scholar
• Baxalta Inc. BabyBIG (botulism immune globulin intravenous [human]). Full prescribing information. Westlake Village (CA, USA): Baxalta Inc; 2015.
   Google Scholar
• Emergent BioSolutions. BAT (botulism antitoxin heptavalent). Full prescribing information. Winnipeg (MB, Canada): Emergent BioSolutions; 2017.
   Google Scholar
• Emergent BioSolutions. BioThrax (anthrax vaccine adsorbed). Full prescribing information. Lansing (MI, USA): Emergent BioSolutions; 2015.
   Google Scholar
• Shirkey HC. Tetanus immune globulin (human) in prophylaxis against tetanus. J Pediatr. 1965;67(4):643–46. doi:https://doi.org/10.1016/s0022-3476(65)80436-x.
   PubMed Web of Science ®Google Scholar
• Rasetti-Escargueil C, Popoff MR. Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins (Basel). 2019;11(9):528. doi:https://doi.org/10.3390/toxins11090528.
   Web of Science ®Google Scholar
• May ML, Corkeron MA, Stretton M. Infant botulism in Australia: availability of human botulinum antitoxin for treatment. Med J Aust. 2010;193(10):614–15. doi:https://doi.org/10.5694/j.1326-5377.2010.tb04073.x.
   PubMedGoogle Scholar
• Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462–71. doi:https://doi.org/10.1056/NEJMoa051926.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Code of federal regulations title 21 - subpart I: approval of new drug when human efficacy studies are not ethical or feasible. [accessed 2020 December 8]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.9.
   Google Scholar
• U.S. Food and Drug Administration. Code of federal regulations title 21 - subpart H: approval of biological products when human efficacy studies are not ethical or feasible. [accessed 2020 December 8]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=601&showFR=1&subpartNode=21:7.0.1.1.2.8.
   Google Scholar
• Allio T. Regulatory pathways for medical products used in biodefense. In: Defense against biological attacks. Cham, Switzerland: Springer Nature Switzerland AG; 2019. p. 283–96.
   Google Scholar
• Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK, Gu W, Clements J, Kim H-J, Rao AK. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis. 2017;66(suppl_1):S57–S64. doi:https://doi.org/10.1093/cid/cix816.
   PubMedGoogle Scholar
• Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C, Babinchak T. Safety and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the United States. Clin Infect Dis. 2020;70(9):1950–57. doi:https://doi.org/10.1093/cid/ciz515.
   PubMed Web of Science ®Google Scholar
• Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):e130687. doi:https://doi.org/10.3201/eid2002.130687.
   PubMedGoogle Scholar
• Cui X, Nolen LD, Sun J, Booth M, Donaldson L, Quinn CP, Boyer AE, Hendricks K, Shadomy S, Bothma P, et al. Analysis of anthrax immune globulin intravenous with antimicrobial treatment in injection drug users, Scotland, 2009-2010. Emerg Infect Dis. 2017;23(1):56–65. doi:https://doi.org/10.3201/eid2301.160608.
   PubMedGoogle Scholar
• Vollman KE, Acquisto NM, Bodkin RP. A case of tetanus infection in an adult with a protective tetanus antibody level. Am J Emerg Med. 2014;32(4):392e393–394. doi:https://doi.org/10.1016/j.ajem.2013.10.025.
   Google Scholar
• Williams DJ, Faiz MA, Abela-Ridder B, Ainsworth S, Bulfone TC, Nickerson AD, Habib AG, Junghanss T, Fan HW, Turner M, et al. Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming. PLoS Negl Trop Dis. 2019;13(2):e0007059. doi:https://doi.org/10.1371/journal.pntd.0007059.
   PubMed Web of Science ®Google Scholar
• Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, McNally J, Kitchens CS, Curry SC, Bogdan GM, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030–36. doi:https://doi.org/10.1001/archinte.161.16.2030.
   PubMed Web of Science ®Google Scholar
• Mascarenas DN, Fullerton L, Smolinske SC, Warrick BJ, Seifert SA. Comparison of F(ab’)2 and Fab antivenoms in rattlesnake envenomation: first year’s post-marketing experience with F(ab’)2 in New Mexico. Toxicon. 2020;186:42–45. doi:https://doi.org/10.1016/j.toxicon.2020.08.002.
   PubMed Web of Science ®Google Scholar
• Gerardo CJ, Quackenbush E, Lewis B, Rose SR, Greene S, Toschlog EA, Charlton NP, Mullins ME, Schwartz R, Denning D. The efficacy of Crotalidae polyvalent immune Fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: a randomized, double-blind, placebo-controlled, clinical trial. Ann Emerg Med. 2017;70(2):233–244. e233. doi:https://doi.org/10.1016/j.annemergmed.2017.04.034.
   PubMed Web of Science ®Google Scholar
• Offerman SR, Daubert GP, Clark RF. The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series. Perm J. 2011;15(3):76–81. doi:https://doi.org/10.7812/tpp/10-136.
   PubMedGoogle Scholar
• Hurst NB, Lipe DN, Karpen SR, Patanwala AE, Taylor AM, Boesen KJ, Shirazi FM. Centruroides sculpturatus envenomation in three adult patients requiring treatment with antivenom. Clin Toxicol (Phila). 2018;56(4):294–96. doi:https://doi.org/10.1080/15563650.2017.1371310.
   PubMed Web of Science ®Google Scholar
• Hauke TJ, Herzig V. Dangerous arachnids-Fake news or reality? Toxicon. 2017;138:173–83. doi:https://doi.org/10.1016/j.toxicon.2017.08.024.
   PubMed Web of Science ®Google Scholar
• Boyer LV, Theodorou AA, Berg RA, Mallie J, Arizona Envenomation I, Chavez-Mendez A, Garcia-Ubbelohde W, Hardiman S, Alagon A. Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med. 2009;360(20):2090–98. doi:https://doi.org/10.1056/NEJMoa0808455.
   PubMed Web of Science ®Google Scholar
• Seifert SA. Abstracts from Venom Week 2009, June 1–4, 2009 Albuquerque, NM. J Med Toxicol. 2010;6(2):234–66. doi:https://doi.org/10.1007/s13181-010-0094-6.
   Google Scholar
• Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;2(8154):1216–17. doi:https://doi.org/10.1016/s0140-6736(79)92335-3.
   PubMed Web of Science ®Google Scholar
• Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol. 2003;77(18):9894–905. doi:https://doi.org/10.1128/jvi.77.18.9894-9905.2003.
   PubMedGoogle Scholar
• Medina RA, Mirowsky-Garcia K, Hutt J, Hjelle B. Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model. J Gen Virol. 2007;88(Pt2):493–505. doi:https://doi.org/10.1099/vir.0.82459-0.
   PubMedGoogle Scholar
• Vial PA, Valdivieso F, Calvo M, Rioseco ML, Riquelme R, Araneda A, Tomicic V, Graf J, Paredes L, Florenzano M, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther. 2015;20(4):377–86. doi:https://doi.org/10.3851/IMP2875.
   PubMed Web of Science ®Google Scholar
• Cao RY, Han JF, Jiang T, Tian X, Yu M, Deng YQ, Qin ED, Qin CF. In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors. J Clin Virol. 2011;51(4):246–49. doi:https://doi.org/10.1016/j.jcv.2011.05.002.
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450–51. doi:https://doi.org/10.1056/NEJMc070359.
   PubMed Web of Science ®Google Scholar
• Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab’)2 in mice. Respir Res. 2006;7:43. doi:https://doi.org/10.1186/1465-9921-7-43.
   PubMedGoogle Scholar
• Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12:489.
   PubMedGoogle Scholar
• Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A. 2012;109(13):5034–39. doi:https://doi.org/10.1073/pnas.1200409109.
   PubMed Web of Science ®Google Scholar
• Makhoul B, Braun E, Herskovitz M, Ramadan R, Hadad S, Norberto K. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J. 2009;11:151–53.
   PubMed Web of Science ®Google Scholar
• Srivastava R, Ramakrishna C, Cantin E. Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. J Gen Virol. 2015;96(Pt6):1347–57. doi:https://doi.org/10.1099/vir.0.000079.
   PubMedGoogle Scholar
• Gnann JW Jr., Agrawal A, Hart J, Buitrago M, Carson P, Hanfelt-Goade D, Tyler K, Spotkov J, Freifeld A, Moore T, et al. Lack of efficacy of high-titered immunoglobulin in patients with West Nile virus central nervous system disease. Emerg Infect Dis. 2019;25(11):2064–73. doi:https://doi.org/10.3201/eid2511.190537.
   PubMed Web of Science ®Google Scholar
• Frame JD, Verbrugge GP, Gill RG, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg. 1984;78(3):319–24. doi:https://doi.org/10.1016/0035-9203(84)90107-x.
   PubMed Web of Science ®Google Scholar
• Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V, Buckland R, Wild TF. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol. 2006;80(4):1972–78. doi:https://doi.org/10.1128/JVI.80.4.1972-1978.2006.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xie YW, Hong J, Zhang X, Kwok SY, Huang X, Wong SW, Wong BL, Group SA. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion. 2005;45(7):1160–64. doi:https://doi.org/10.1111/j.1537-2995.2005.00179.x.
   PubMed Web of Science ®Google Scholar
• Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, Wan HL, Chen JH, Hu BS, Perng CL, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–22. doi:https://doi.org/10.1093/jac/dki346.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi:https://doi.org/10.1007/s10096-004-1271-9.
   PubMed Web of Science ®Google Scholar
• Scott SSO, Braga-Neto P, Pereira LP, Nobrega PR, de Assis Aquino Gondim F, Sobreira-Neto MA, Schiavon CCM. Immunoglobulin-responsive chikungunya encephalitis: two case reports. J Neurovirol. 2017;23(4):625–31. doi:https://doi.org/10.1007/s13365-017-0535-y.
   PubMedGoogle Scholar
• Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200(4):516–23. doi:https://doi.org/10.1086/600381.
   PubMed Web of Science ®Google Scholar
• Fernandes AIV, Souza JR, Silva AR, Cruz S, Castellano LRC. Immunoglobulin therapy in a patient with severe Chikungunya fever and vesiculobullous lesions. Front Immunol. 2019;10:1498. doi:https://doi.org/10.3389/fimmu.2019.01498.
   PubMedGoogle Scholar
• Erduran E, Bahadir A, Palanci N, Gedik Y. The treatment of Crimean-Congo hemorrhagic fever with high-dose methylprednisolone, intravenous immunoglobulin, and fresh frozen plasma. J Pediatr Hematol Oncol. 2013;35(1):e19–24. doi:https://doi.org/10.1097/MPH.0b013e3182706444.
   PubMedGoogle Scholar
• Salehi H, Salehi M, Adibi N, Salehi M. Comparative study between ribavirin and ribavirin plus intravenous immunoglobulin against Crimean Congo hemorrhagic fever. J Res Med Sci. 2013;18:497–500.
   PubMed Web of Science ®Google Scholar
• Kubar A, Haciomeroglu M, Ozkul A, Bagriacik U, Akinci E, Sener K, Bodur H. Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis. 2011;64:439–43.
   PubMed Web of Science ®Google Scholar
• Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464–73. doi:https://doi.org/10.1378/chest.12-2907.
   PubMed Web of Science ®Google Scholar
• Chong JL, Sapari S, Kuan YC. A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect. 2011;44(4):319–22. doi:https://doi.org/10.1016/j.jmii.2010.07.001.
   PubMedGoogle Scholar
• Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–56. doi:https://doi.org/10.1093/cid/ciq106.
   PubMed Web of Science ®Google Scholar
• Gordon CL, Langan K, Charles PG, Bellomo R, Hart GK, Torresi J, Johnson PD, Grayson ML. Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin Infect Dis. 2011;52(3):422–26. doi:https://doi.org/10.1093/cid/ciq082.
   PubMed Web of Science ®Google Scholar
• Gouveia FL, Oliveira R, Lucena A, Cordeiro MT, Leite ACL. Production of intravenous human dengue immunoglobulin from Brazilian-blood donors. Braz J Pharm Sci. 2013;49:821–29. doi:https://doi.org/10.1590/S1984-82502013000400022.
   Google Scholar
• Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, Davey RT Jr. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18(4):410–18. doi:https://doi.org/10.1016/S1473-3099(18)30002-1.
   PubMed Web of Science ®Google Scholar
• Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, Kim YJ, Park JK, Chung CR, Kang ES, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617–22. doi:https://doi.org/10.3851/IMP3243.
   PubMed Web of Science ®Google Scholar
• Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709. doi:https://doi.org/10.1186/s40064-015-1490-9.
   PubMed Web of Science ®Google Scholar
• Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis. 2015;41:3–5. doi:https://doi.org/10.1016/j.ijid.2015.10.009.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi:https://doi.org/10.1056/NEJMoa1511812.
   PubMed Web of Science ®Google Scholar
• Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, Baker S, Nicol S, Conton B, Johnson W, et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect. 2017;74(3):302–09. doi:https://doi.org/10.1016/j.jinf.2016.11.009.
   PubMed Web of Science ®Google Scholar
• Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496–502. doi:https://doi.org/10.1093/cid/civ334.
   PubMed Web of Science ®Google Scholar
• Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, et al. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep. 2017;7(1):4099. doi:https://doi.org/10.1038/s41598-017-03910-7.
   PubMedGoogle Scholar
• Wang H, Wong G, Zhu W, He S, Zhao Y, Yan F, Rahim MN, Bi Y, Zhang Z, Cheng K, et al. Equine-origin immunoglobulin fragments protect nonhuman primates from Ebola virus disease. J Virol. 2019;93(5):e01548–01518. doi:https://doi.org/10.1128/JVI.01548-18.
   PubMed Web of Science ®Google Scholar
• Branche E, Simon AY, Sheets N, Kim K, Barker D, Nguyen AT, Sahota H, Young MP, Salgado R, Mamidi A, et al. Human polyclonal antibodies prevent lethal Zika virus infection in mice. Sci Rep. 2019;9(1):9857. doi:https://doi.org/10.1038/s41598-019-46291-9.
   PubMedGoogle Scholar
• Berry N, Kempster S, Ham C, Jenkins A, Hall J, Page M, Mattiuzzo G, Adedeji Y, Hewson R, Giles E, et al. Passive immunisation of convalescent human anti-Zika plasma protects against challenge with New World Zika virus in cynomolgus macaques. NPJ Vaccines. 2020;5:86. doi:https://doi.org/10.1038/s41541-020-00234-y.
   PubMedGoogle Scholar
• Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–89. doi:https://doi.org/10.1001/jama.2020.4783.
   PubMed Web of Science ®Google Scholar
• Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26(11):1708–13. doi:https://doi.org/10.1038/s41591-020-1088-9.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–96. doi:https://doi.org/10.1073/pnas.2004168117.
   PubMed Web of Science ®Google Scholar
• Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008;451(7181):990–93. doi:https://doi.org/10.1038/nature06536.
   PubMed Web of Science ®Google Scholar
• Priyadarsini SL, Suresh M, Huisingh D. What can we learn from previous pandemics to reduce the frequency of emerging infectious diseases like COVID-19? Glob Transit. 2020;2:202–20. doi:https://doi.org/10.1016/j.glt.2020.09.003.
   PubMedGoogle Scholar
• Marston HD, Folkers GK, Morens DM, Fauci AS. Emerging viral diseases: confronting threats with new technologies. Sci Transl Med. 2014;6(253):253ps210. doi:https://doi.org/10.1126/scitranslmed.3009872.
   Web of Science ®Google Scholar
• Lobermann M, Borso D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11(3):212–18. doi:https://doi.org/10.1016/j.autrev.2011.05.015.
   PubMed Web of Science ®Google Scholar
• Thijssen M, Devos T, Ejtahed HS, Amini-Bavil-Olyaee S, Pourfathollah AA, Pourkarim MR. Convalescent plasma against COVID-19: a broad-spectrum therapeutic approach for emerging infectious diseases. Microorganisms. 2020;8(11):1733. doi:https://doi.org/10.3390/microorganisms8111733.
   Google Scholar
• Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561–62. doi:https://doi.org/10.1001/jama.2020.4940.
   PubMed Web of Science ®Google Scholar
• Ciencewicki JM, Schouest KR, Gierman TM, Vandeberg PJ, Gooch BD. Plasma donors in the southwestern United States positively contribute to the diverse therapeutic antibody profile of immune globulin products. Sci Rep. 2020;10(1):6850. doi:https://doi.org/10.1038/s41598-020-63794-y.
   PubMedGoogle Scholar
• Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46. doi:https://doi.org/10.1016/j.jaci.2016.09.023.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. CFR - Code of federal regulations title 21. [accessed 2020 December 8]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=640&showFR=1&subpartNode=21:7.0.1.1.7.10
   Google Scholar
• Garraud O. Use of convalescent plasma in Ebola virus infection. Transfus Apher Sci. 2017;56(1):31–34. doi:https://doi.org/10.1016/j.transci.2016.12.014.
   PubMedGoogle Scholar
• VanBlargan LA, Goo L, Pierson TC. Deconstructing the antiviral neutralizing-antibody response: implications for vaccine development and immunity. Microbiol Mol Biol Rev. 2016;80(4):989–1010. doi:https://doi.org/10.1128/MMBR.00024-15.
   PubMed Web of Science ®Google Scholar
• Vanderven HA, Kent SJ. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol Cell Biol. 2020;98(4):253–63. doi:https://doi.org/10.1111/imcb.12312.
   PubMedGoogle Scholar
• Martins KA, Gregory MK, Valdez SM, Sprague TR, Encinales L, Pacheco N, Cure C, Porras-Ramirez A, Rico-Mendoza A, Chang A, et al. Neutralizing antibodies from convalescent Chikungunya virus patients can cross-neutralize Mayaro and Una viruses. Am J Trop Med Hyg. 2019;100(6):1541–44. doi:https://doi.org/10.4269/ajtmh.18-0756.
   PubMedGoogle Scholar
• Fox JM, Huang L, Tahan S, Powell LA, Crowe JE Jr., Wang D, Diamond MS A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. PLoS Pathog. 2020;16(8):e1008743. doi:https://doi.org/10.1371/journal.ppat.1008743.
   PubMed Web of Science ®Google Scholar
• Venturi G, Zammarchi L, Fortuna C, Remoli ME, Benedetti E, Fiorentini C, Trotta M, Rizzo C, Mantella A, Rezza G, Bartoloni A. An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, 2014. Eurosurveillance. 2016;21(8):30148. doi:https://doi.org/10.2807/1560-7917.ES.2016.21.8.30148.
   Web of Science ®Google Scholar
• Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016;374(16):1552–63. doi:https://doi.org/10.1056/NEJMra1602113.
   PubMed Web of Science ®Google Scholar
• Petersen EE, Meaney-Delman D, Neblett-Fanfair R, Havers F, Oduyebo T, Hills SL, Rabe IB, Lambert A, Abercrombie J, Martin SW, et al. Update: interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for persons with possible zika virus exposure - United States, Sep 2016. MMWR Morb Mortal Wkly Rep. 2016;65(39):1077–81. doi:https://doi.org/10.15585/mmwr.mm6539e1.
   PubMed Web of Science ®Google Scholar
• Ai JW, Zhang Y, Zhang W. Zika virus outbreak: ‘a perfect storm’. Emerg Microbes Infect. 2016;5(1):e21. doi:https://doi.org/10.1038/emi.2016.42.
   PubMedGoogle Scholar
• World Health Organization. Zika epidemiology update. [accessed 2020 December 8]. https://www.who.int/emergencies/diseases/zika/zika-epidemiology-update-july-2019.pdf
   Google Scholar
• Uncini A, Shahrizaila N, Kuwabara S. Zika virus infection and Guillain-Barre syndrome: a review focused on clinical and electrophysiological subtypes. J Neurol Neurosurg Psychiatry. 2017;88(3):266–71. doi:https://doi.org/10.1136/jnnp-2016-314310.
   PubMedGoogle Scholar
• Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the risk of microcephaly. N Engl J Med. 2016;375(1):1–4. doi:https://doi.org/10.1056/NEJMp1605367.
   PubMed Web of Science ®Google Scholar
• Ventura CV, Maia M, Travassos SB, Martins TT, Patriota F, Nunes ME, Agra C, Torres VL, van der Linden V, Ramos RC, et al. Risk factors associated with the ophthalmoscopic findings identified in infants with presumed Zika virus congenital infection. JAMA Ophthalmol. 2016;134(8):912–18. doi:https://doi.org/10.1001/jamaophthalmol.2016.1784.
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects–reviewing the evidence for causality. N Engl J Med. 2016;374(20):1981–87. doi:https://doi.org/10.1056/NEJMsr1604338.
   PubMed Web of Science ®Google Scholar
• Brasil P, Pereira JP Jr., Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, Rabello RS, Valderramos SG, Halai UA, Salles TS, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375(24):2321–34. doi:https://doi.org/10.1056/NEJMoa1602412.
   PubMed Web of Science ®Google Scholar
• Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, Kolenc M, Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodusek V, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951–58. doi:https://doi.org/10.1056/NEJMoa1600651.
   PubMed Web of Science ®Google Scholar
• Stein DR, Golden JW, Griffin BD, Warner BM, Ranadheera C, Scharikow L, Sloan A, Frost KL, Kobasa D, Booth SA, et al. Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice. Antiviral Res. 2017;146:164–73. doi:https://doi.org/10.1016/j.antiviral.2017.09.005.
   PubMed Web of Science ®Google Scholar
• Siddharthan V, Miao J, Van Wettere AJ, Li R, Wu H, Sullivan E, Jiao J, Hooper JW, Safronetz D, Morrey JD, et al. Human polyclonal antibodies produced from transchromosomal bovine provides prophylactic and therapeutic protections against Zika virus infection in STAT2 KO Syrian hamsters. Viruses. 2019;11(2):92. doi:https://doi.org/10.3390/v11020092.
   Google Scholar
• Kamada Ltd. Kamada provides update on progress related to its proprietary hyper-immunoglobulin (IgGs) platform technology including its commercial anti-rabies IgG and its pipeline products anti-corona (COVID-19) and Anti-Zika IgGs. [accessed 2020 December 8]. https://www.biospace.com/article/releases/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19-and-anti-zika-iggs/.
   Google Scholar
• Maciejewski S, Ruckwardt TJ, Morabito KM, Foreman BM, Burgomaster KE, Gordon DN, Pelc RS, DeMaso CR, Ko S-Y, Fisher BE, et al. Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci Transl Med. 2020;12(547):eaaw9066. doi:https://doi.org/10.1126/scitranslmed.aaw9066.
   Google Scholar
• Shan C, Xie X, Luo H, Muruato AE, Liu Y, Wakamiya M, La JH, Chung JM, Weaver SC, Wang T, et al. Maternal vaccination and protective immunity against Zika virus vertical transmission. Nat Commun. 2019;10(1):5677. doi:https://doi.org/10.1038/s41467-019-13589-1.
   PubMedGoogle Scholar
• Van Rompay KK, Keesler RI, Ardeshir A, Watanabe J, Usachenko J, Singapuri A, Cruzen C, Bliss-Moreau E, Murphy AM, Yee JL. DNA vaccination before conception protects Zika virus–exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Sci Transl Med. 2019;11(523).
   PubMed Web of Science ®Google Scholar
• Fouda GG, Martinez DR, Swamy GK, Permar SR. The impact of IgG transplacental transfer on early life immunity. Immunohorizons. 2018;2(1):14–25. doi:https://doi.org/10.4049/immunohorizons.1700057.
   PubMedGoogle Scholar
• Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014;370(14):1316–26. doi:https://doi.org/10.1056/NEJMoa1310214.
   PubMed Web of Science ®Google Scholar
• Eke AC, Eleje GU, Eke UA, Xia Y, Liu J. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst Rev. 2017;2(2):CD008545. doi:https://doi.org/10.1002/14651858.CD008545.pub2.
   PubMedGoogle Scholar
• Cromwell C, Tarantino M, Aledort LM. Safety of anti-D during pregnancy. Am J Hematol. 2009;84(4):261–62. doi:https://doi.org/10.1002/ajh.21376.
   PubMedGoogle Scholar
• Pantoja P, Perez-Guzman EX, Rodriguez IV, White LJ, Gonzalez O, Serrano C, Giavedoni L, Hodara V, Cruz L, Arana T, et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017;8:15674. doi:https://doi.org/10.1038/ncomms15674.
   PubMed Web of Science ®Google Scholar
• Chang -H-H, Huber RG, Bond PJ, Grad YH, Camerini D, Maurer-Stroh S, Lipsitch M. Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bull World Health Organ. 2017;95(7):517. doi:https://doi.org/10.2471/BLT.16.182105.
   PubMedGoogle Scholar
• Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerging Microbes Infect. 2019;6(1):1–6. doi:https://doi.org/10.1038/emi.2017.42.
   Google Scholar
• Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32. doi:https://doi.org/10.1126/science.aan6836.
   PubMed Web of Science ®Google Scholar
• Masel J, McCracken MK, Gleeson T, Morrison B, Rutherford G, Imrie A, Jarman RG, Koren M, Pollett S. Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned. PLoS Negl Trop Dis. 2019;13(1):e0007060. doi:https://doi.org/10.1371/journal.pntd.0007060.
   PubMedGoogle Scholar
• McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, Eckles KH, Garver LS, Boyd M, Jetton D, et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog. 2017;13(8):e1006487. doi:https://doi.org/10.1371/journal.ppat.1006487.
   PubMedGoogle Scholar
• Ribeiro GS, Kikuti M, Tauro LB, Nascimento LCJ, Cardoso CW, Campos GS, Ko AI, Weaver SC, Reis MG, Kitron U, on behalf of the Salvador Arboviral Research Group. Does immunity after Zika virus infection cross-protect against dengue? Lancet Global Health. 2018;6(2):e140–e141. doi:https://doi.org/10.1016/S2214-109X(17)30496-5.
   PubMedGoogle Scholar
• Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, Simonsen L, Viboud C. Global seasonal influenza-associated mortality collaborator network and GLaMOR collaborating teams. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421. doi:https://doi.org/10.7189/jogh.09.020421.
   PubMed Web of Science ®Google Scholar
• Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383–97. doi:https://doi.org/10.1038/s41577-019-0143-6.
   PubMed Web of Science ®Google Scholar
• Su S, Chaves SS, Perez A, D’Mello T, Kirley PD, Yousey-Hindes K, Farley MM, Harris M, Sharangpani R, Lynfield R, et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis. 2014;59:252–55. doi:https://doi.org/10.1093/cid/ciu269.
   PubMed Web of Science ®Google Scholar
• Moscona A. Oseltamivir resistance—disabling our influenza defenses. N Engl J Med. 2005;353:2633–36. doi:https://doi.org/10.1056/NEJMp058291.
   PubMed Web of Science ®Google Scholar
• Padilla-Quirarte HO, Lopez-Guerrero DV, Gutierrez-Xicotencatl L, Esquivel-Guadarrama F. Protective antibodies against influenza proteins. Front Immunol. 2019;10:1677. doi:https://doi.org/10.3389/fimmu.2019.01677.
   PubMedGoogle Scholar
• Neerukonda SN, Vassell R, Weiss CD. Neutralizing antibodies targeting the conserved stem region of influenza hemagglutinin. Vaccines. 2020;8(3):382. doi:https://doi.org/10.3390/vaccines8030382.
   Google Scholar
• Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, Lee J, Wan H, Rojas KT, Kirkpatrick E, et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell. 2018;173(2):417–429e410. doi:https://doi.org/10.1016/j.cell.2018.03.030.
   PubMed Web of Science ®Google Scholar
• Lee CC, Yang CY, Lin LL, Ko TP, Chang AH, Chang SS, Wang AH. An effective neutralizing antibody against influenza virus H1N1 from human B cells. Sci Rep. 2019;9(1):4546. doi:https://doi.org/10.1038/s41598-019-40937-4.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, Garcia-Sastre A, Bouvier NM, et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol. 2017;18(4):464–73. doi:https://doi.org/10.1038/ni.3684.
   PubMed Web of Science ®Google Scholar
• Kim JH, Reber AJ, Kumar A, Ramos P, Sica G, Music N, Guo Z, Mishina M, Stevens J, York IA, et al. Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease. Sci Rep. 2016;6:37341. doi:https://doi.org/10.1038/srep37341.
   PubMedGoogle Scholar
• Arunkumar GA, Ioannou A, Wohlbold TJ, Meade P, Aslam S, Amanat F, Ayllon J, García-Sastre A, Krammer F. Broadly cross-reactive, nonneutralizing antibodies against influenza B virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice. J Virol. 2019;93(6):e01696-18. doi:https://doi.org/10.1128/JVI.01696-18.
   Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi:https://doi.org/10.1093/infdis/jiu396.
   PubMed Web of Science ®Google Scholar
• Vanderven HA, Wragg K, Ana-Sosa-Batiz F, Kristensen AB, Jegaskanda S, Wheatley AK, Wentworth D, Wines BD, Hogarth PM, Rockman S, et al. Anti-influenza hyperimmune immunoglobulin enhances Fc-functional antibody immunity during human influenza infection. J Infect Dis. 2018;218(9):1383–93. doi:https://doi.org/10.1093/infdis/jiy328.
   PubMedGoogle Scholar
• Hohenadl C, Wodal W, Kerschbaum A, Fritz R, Howard MK, Farcet MR, Portsmouth D, McVey JK, Baker DA, Ehrlich HJ, et al. Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice. Virol J. 2014;11(1):70. doi:https://doi.org/10.1186/1743-422X-11-70.
   PubMedGoogle Scholar
• Herbreteau CH, Denizot M, Lowther S, Riddell S, Frazer L, Haining J, Arkinstall R, Payne J, Harper J, Johnson D, et al. Efficacy of a specific polyclonal equine F(ab’)2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir. Immunotherapy. 2016;8(9):1021–32. doi:https://doi.org/10.2217/imt-2016-0062.
   PubMedGoogle Scholar
• Qiu H, Andersen H, Tarbet EB, Muhammad FS, Carnelley T, Pronyk R, Barker D, Kodihalli S. Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus. Antiviral Res. 2020;180:104753. doi:https://doi.org/10.1016/j.antiviral.2020.104753.
   PubMedGoogle Scholar
• Belser J, Katz J, Tumpey T. The ferret as a model organism to study influenza A virus infection. Dis Model Mech. 2011;4:575–79. doi:https://doi.org/10.1242/dmm.007823.
   PubMed Web of Science ®Google Scholar
• INSIGHT FLU005 IVIG Pilot Study Group. INSIGHT FLU005: an anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. J Infect Dis. 2016;213(4):574–78. doi:https://doi.org/10.1093/infdis/jiv453.
   PubMedGoogle Scholar
• Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019;7(11):951–63. doi:https://doi.org/10.1016/S2213-2600(19)30253-X.
   PubMedGoogle Scholar
• Kanjilal S, Mina MJ. Passive immunity for the treatment of influenza: quality not quantity. Lancet Respir Med. 2019;7(11):922–23. doi:https://doi.org/10.1016/S2213-2600(19)30265-6.
   PubMedGoogle Scholar
• World Health Organization. WHO coronavirus disease (COVID-19) dashboard. [accessed 2020 September 30]. https://covid19.who.int/
   Google Scholar
• Plasma Protein Therapeutics Association. [accessed 2020 December 8]. https://www.pptaglobal.org/
   Google Scholar
• Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. doi:https://doi.org/10.1038/s41577-020-0311-8.
   PubMed Web of Science ®Google Scholar
• Fung M, Nambiar A, Pandey S, Aldrich JM, Teraoka J, Freise C, Roberts J, Chandran S, Hays SR, Bainbridge E, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2020;e13477. doi:https://doi.org/10.1111/tid.13477.
   Google Scholar
• Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, Percivalle E, Glingani C, Musella V, Belliato M, et al. 2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Haematologica. 2020;105(12):2834–2840. doi:https://doi.org/10.3324/haematol.2020.261784.
   Google Scholar
• Perotti C, Del Fante C, Baldanti F, Franchini M, Percivalle E, Vecchio Nepita E, Seminari E, De Silvestri A, Bruno R, Klersy C. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. Intern Emerg Med. 2020;15(5):819–24. doi:https://doi.org/10.1007/s11739-020-02384-2.
   PubMed Web of Science ®Google Scholar
• Khulood D, Adil MS, Sultana R, Nimra. Convalescent plasma appears efficacious and safe in COVID-19. Ther Adv Infect Dis. 2020;7:2049936120957931. doi:https://doi.org/10.1177/2049936120957931.
   Web of Science ®Google Scholar
• Dogan M, Kozhaya L, Placek L, Gunter C, Yigit M, Hardy R, Plassmeyer M, Coatney P, Lillard K, Bukhari Z, et al. Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19. medRxiv. 2020; doi:https://doi.org/10.1101/2020.07.07.20148106.
   PubMedGoogle Scholar
• Estcourt LJ, Roberts DJ. Convalescent plasma for COVID-19. BMJ. 2020;370:m3516. doi:https://doi.org/10.1136/bmj.m3516.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. EUA 26382: emergency use authorization (EUA) request. 2020.
   Google Scholar
• Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152–57. doi:https://doi.org/10.2450/2015.0131-15.
   PubMed Web of Science ®Google Scholar
• Steffen TL, Stone ET, Hassert M, Geerling E, Grimberg BT, Espino AM, Pantoja P, Climent C, Hoft DF, George SL. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. bioRxiv. 2020; preprint. doi:https://doi.org/10.1101/2020.08.07.241877.
   Google Scholar
• Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–55. doi:https://doi.org/10.1126/science.abc6952.
   PubMed Web of Science ®Google Scholar
• Yan R, Wang R, Ju B, Yu J, Zhang Y, Liu N, Wang J, Zhang Q, Chen P, Zhou B, et al. 2020. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. bioRxiv. 2020;preprint. doi:https://doi.org/10.1101/2020.10.13.336800
   Google Scholar
• Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–30. doi:https://doi.org/10.1126/science.abd7728.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clin Infect Dis. 2020:ciaa721. doi:https://doi.org/10.1093/cid/ciaa721.
   Google Scholar
• Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S, Naik HM, Betenbaugh MJ, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141–50. doi:https://doi.org/10.1172/JCI142004.
   PubMed Web of Science ®Google Scholar
• Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):e3000003. doi:https://doi.org/10.1371/journal.pbio.3000003.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen J, Gao K, Hozumi Y, Yin C, Wei G. Characterizing SARS-CoV-2 mutations in the United States. Res Sq. 2020. doi:https://doi.org/10.21203/rs.3.rs-49671/v1.
   Google Scholar
• Wang R, Hozumi Y, Yin C, Wei GW. Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID-19 diagnosis, vaccine, and medicine. J Chem Inf Model. 2020;60:5853–65. doi:https://doi.org/10.1021/acs.jcim.0c00501.
   PubMed Web of Science ®Google Scholar
• Van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, Pentelute BL, Carlson JM, Hixon M, Joseph-McCarthy D, et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv. 2020; doi:https://doi.org/10.1101/2020.11.17.20233726.
   Google Scholar
• Lee CY-P, Amrun SN, Chee RS-L, Goh YS, Mak T-M, Octavia S, Yeo NK-W, Chang ZW, Tay MZ, Torres-Ruesta A, et al. Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant. bioRxiv. 2020; doi:https://doi.org/10.1101/2020.10.08.332544.
   Google Scholar
• Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.06.12.148726.
   Google Scholar
• Klumpp-Thomas C, Kalish H, Hicks J, Mehalko J, Drew M, Memoli MJ, Hall MD, Esposito D, Sadtler K. D614G spike variant does not alter IgG, IgM, or IgA spike seroassay performance. medRxiv. 2020; 2020.2007.2008.20147371. doi:https://doi.org/10.1101/2020.07.08.20147371.
   Google Scholar
• Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, et al. The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. bioRxiv. 2020; 2020.2011.2004.355842. doi:https://doi.org/10.1101/2020.11.04.355842.
   Google Scholar
• Clinicaltrials.gov. Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients (SECR-01). [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04610502.
   Google Scholar
• Clinicaltrials.gov. Safety and efficacy of anti-SARS-CoV-2 equine antibody fragments (INOSARS) for hospitalized patients with COVID-19. [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04514302.
   Google Scholar
• Clinicaltrials.gov. Treatment with anti-SARS-CoV-2 immunoglobulin in patients with COVID-19. [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04573855.
   Google Scholar
• Clinicaltrials.gov. A study to investigate the pharmacokinetics, efficacy and safety of INM005 in patients with COVID-19. [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04494984.
   Google Scholar
• Clinicaltrials.gov. Safety, tolerability, and pharmacokinetics of SAB-185 in healthy participants. [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04468958.
   Google Scholar
• Clinicaltrials.gov. Safety, tolerability, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19. [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04469179.
   Google Scholar
• Monzani PS, Adona PR, Ohashi OM, Meirelles FV, Wheeler MB. Transgenic bovine as bioreactors: challenges and perspectives. Bioengineered. 2016;7(3):123–31. doi:https://doi.org/10.1080/21655979.2016.1171429.
   PubMed Web of Science ®Google Scholar
• Gardner CL, Sun C, Luke T, Raviprakash K, Wu H, Jiao JA, Sullivan E, Reed DS, Ryman KD, Klimstra WB. Antibody preparations from human transchromosomic cows exhibit prophylactic and therapeutic efficacy against Venezuelan equine encephalitis virus. J Virol. 2017;91(14):e00226–00217. doi:https://doi.org/10.1128/JVI.00226-17.
   PubMedGoogle Scholar
• Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, et al. Production of potent fully human polyclonal antibodies against Ebola Zaire Virus in transchromosomal cattle. Sci Rep. 2016;6(1):24897. doi:https://doi.org/10.1038/srep24897.
   PubMedGoogle Scholar
• Rosenke K, Bounds CE, Hanley PW, Saturday G, Sullivan E, Wu H, Jiao JA, Feldmann H, Schmaljohn C, Safronetz D. Human polyclonal antibodies produced by transchromosomal cattle provide partial protection against lethal Zaire Ebolavirus challenge in rhesus macaques. J Infect Dis. 2018;218(suppl_5):S658–S661. doi:https://doi.org/10.1093/infdis/jiy430.
   PubMedGoogle Scholar
• Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8(326):326ra321. doi:https://doi.org/10.1126/scitranslmed.aaf1061.
   Web of Science ®Google Scholar
• SAb Biotherapeutics. SAb biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza. [accessed 2020 November 18]. https://www.sabbiotherapeutics.com/2020/07/30/sab-biotherapeutics-announces-first-participant-dosed-in-phase-1-clinical-trial-of-sab-176-for-seasonal-influenza/.
   Google Scholar
• SAb Biotherapeutics. SAb biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-185 for the treatment and prevention of COVID-19. [accessed 2020 November 18]. https://www.sabbiotherapeutics.com/2020/08/11/sab-biotherapeutics-announces-first-participant-dosed-in-phase-1-clinical-trial-of-sab-185-for-the-treatment-and-prevention-of-covid-19/.
   Google Scholar
• Vanhove B, Duvaux O, Rousse J, Royer P-J, Evanno G, Ciron C, Lheriteau E, Vacher L, Gervois N, Oger R, et al. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2. bioRxiv. 2020; preprint. doi:https://doi.org/10.1101/2020.07.25.217158.
   Google Scholar
• Clinicaltrials.gov. First in human study: LIS1, an induction treatment in kidney transplanted patients. [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04431219.
   Google Scholar
• Clinicaltrials.gov. Study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia (POLYCOR). [accessed 2020 December 8]. https://clinicaltrials.gov/ct2/show/NCT04453384.
   Google Scholar
• Wang XZ, Coljee VW, Maynard JA. Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng. 2013;2(4):405–15. doi:https://doi.org/10.1016/j.coche.2013.08.005.
   PubMed Web of Science ®Google Scholar
• GigaGen I. GigaGen initiates large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050. [accessed 2020 November 18]. http://www.globenewswire.com/news-release/2020/09/09/2091073/0/en/GigaGen-Initiates-Large-Scale-Manufacturing-of-its-First-in-Class-Recombinant-Hyperimmune-Drug-for-COVID-19-GIGA-2050.html.
   Google Scholar
• Keating SM, Mizrahi RA, Adams MS, Asensio MA, Benzie E, Carter KP, Chiang Y, Edgar RC, Gautam BK, Gras A, et al. Capturing and recreating diverse antibody repertoires as multivalent recombinant polyclonal antibody drugs. bioRxiv. 2020; 2020.2008.2005.232975. doi:https://doi.org/10.1101/2020.08.05.232975.
   Google Scholar
• GigaGen Inc. GigaGen receives NIH grant to develop production technology for recombinant intravenous immunoglobulin. [accessed 2020 November 18]. https://www.prnewswire.com/news-releases/gigagen-receives-nih-grant-to-develop-production-technology-for-recombinant-intravenous-immunoglobulin-300582135.html.
   Google Scholar
• Bodier-Montagutelli E, Mayor A, Vecellio L, Respaud R, Heuze-Vourc’h N. Designing inhaled protein therapeutics for topical lung delivery: what are the next steps? Expert Opin Drug Deliv. 2018;15(8):729–36. doi:https://doi.org/10.1080/17425247.2018.1503251.
   PubMed Web of Science ®Google Scholar
• Respaud R, Vecellio L, Diot P, Heuzé-Vourc’h N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12:1–13. doi:https://doi.org/10.1517/17425247.2015.999039.
   PubMedGoogle Scholar
• Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother. 2015;59(7):4162–72. doi:https://doi.org/10.1128/AAC.00290-15.
   PubMed Web of Science ®Google Scholar
• DeFrancesco L. COVID-19 antibodies on trial. Nat Biotechnol. 2020;38(11):1242–52. doi:https://doi.org/10.1038/s41587-020-0732-8.
   PubMed Web of Science ®Google Scholar
• Vonarburg C, Loetscher M, Spycher MO, Kropf A, Illi M, Salmon S, Roberts S, Steinfuehrer K, Campbell I, Koernig S, et al. Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir Res. 2019;20(1):99. doi:https://doi.org/10.1186/s12931-019-1057-3.
   PubMedGoogle Scholar
• Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100–17. doi:https://doi.org/10.1016/j.addr.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Piepenbrink MS, Park J-G, Oladunni FS, Deshpande A, Basu M, Sarkar S, Loos A, Woo J, Lovalenti P, Sloan D, et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. bioRxiv. 2020; 2020.2010.2014.339150. doi:https://doi.org/10.1101/2020.10.14.339150.
   Google Scholar
• Rees V. 2020. Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials. Eur Pharm Rev. Epub. https://www.europeanpharmaceuticalreview.com/news/130720/inhaled-antibody-treatment-for-covid-19-shows-success-in-pre-clinical-trials/.
   Google Scholar
• Diomics Corp. A human antibody nasal spray under development might have prevented White House infections, scientists at Diomics and Active Motif say. [accessed 2021 January 19]. https://www.prnewswire.com/news-releases/a-human-antibody-nasal-spray-under-development-might-have-prevented-white-house-infections-scientists-at-diomics-and-active-motif-say-301148054.html.
   Google Scholar
• Lai SK, McSweeney MD, Pickles RJ. Learning from past failures: challenges with monoclonal antibody therapies for COVID-19. J Controlled Release. 2021;329:87–95. doi:https://doi.org/10.1016/j.jconrel.2020.11.057.
   PubMedGoogle Scholar
• Zhang H, Yang Z, Xiang J, Cui Z, Liu J, Liu C. Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice. bioRxiv. 2020; doi:https://doi.org/10.1101/2020.12.08.416677.
   Google Scholar
• Gai J, Ma L, Li G, Zhu M, Qiao P, Li X, Zhang H, Zhang Y, Chen Y, Gong R. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. bioRxiv. 2020. doi:https://doi.org/10.1101/2020.08.09.242867.
   Google Scholar
• Hanke L, Vidakovics Perez L, Sheward DJ, Das H, Schulte T, Moliner-Morro A, Corcoran M, Achour A, Karlsson Hedestam GB, Hallberg BM, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun. 2020;11(1):4420. doi:https://doi.org/10.1038/s41467-020-18174-5.
   PubMed Web of Science ®Google Scholar
• Konwarh R. Nanobodies: prospects of expanding the gamut of neutralizing antibodies against the novel coronavirus, SARS-CoV-2. Front Immunol. 2020;11:1531–1531. doi:https://doi.org/10.3389/fimmu.2020.01531.
   PubMed Web of Science ®Google Scholar
• Pérez de la Lastra JM, Baca-González V, Asensio-Calavia P, González-Acosta S, Morales-delaNuez A. Can immunization of hens provide oral-based therapeutics against COVID-19? Vaccines. 2020;8(3):486. doi:https://doi.org/10.3390/vaccines8030486.
   Google Scholar
• Cohen J. Can a nose-full of chicken antibodies ward off coronavirus infections? Science. 2020; [Epub]. doi:https://doi.org/10.1126/science.abf6581.
   Google Scholar